Legal & General Group
LABP

Legal & General Group’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Legal & General Group’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41
Closed -$1K – 3731
2022
Q1 		$1K Hold
41
– – ﹤0.01% 3565
2021
Q4 		$2K Hold
41
– – ﹤0.01% 3572
2021
Q3 		$6K Sell
41
-18
-31% -$2.34K ﹤0.01% 3478
2021
Q2 		$7K Hold
59
– – ﹤0.01% 3450
2021
Q1 		$6K Buy
+59
New +$7.7K ﹤0.01% 3471

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's LABP Position: Q2 2022 in Review

Legal & General Group sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 41 shares — an estimated $1K sold.

Legal & General Group first reported a position in LABP in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q2 2021. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

  • Legal & General Group reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 41 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Legal & General Group first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Legal & General Group's Landos Biopharma, Inc. Common Stock position peaked at $7K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.